Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-230X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer ; volume:17 ; number:1 ; day:23 ; month:11 ; year:2017 ; pages:1-8 ; date:12.2017
BMC gastroenterology ; 17, Heft 1 (23.11.2017), 1-8, 12.2017
- Klassifikation
-
Medizin, Gesundheit
- Urheber
-
Kim, Dalyong
- Beteiligte Personen und Organisationen
-
Kim, Sun Young
Lee, Ji Sung
Hong, Yong Sang
Kim, Jeong Eun
Kim, Kyu-Pyo
Kim, Jihun
Jang, Se Jin
Yoon, Young-Kwang
Kim, Tae Won
SpringerLink (Online service)
- DOI
-
10.1186/s12876-017-0694-6
- URN
-
urn:nbn:de:1111-201801253174
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kim, Dalyong
- Kim, Sun Young
- Lee, Ji Sung
- Hong, Yong Sang
- Kim, Jeong Eun
- Kim, Kyu-Pyo
- Kim, Jihun
- Jang, Se Jin
- Yoon, Young-Kwang
- Kim, Tae Won
- SpringerLink (Online service)
Ähnliche Objekte (12)
![[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer](/assets/placeholder/searchResultMediaUnknown.png)
[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trial
First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS
Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment
Lobaplatin hyperthermic intraperitoneal chemotherapy plus cytoreduction and rechallenge using cetuximab for wild-type RAS peritoneal metastatic colon cancer: a case report and literature review
Controversies in the treatment of RAS wild-type metastatic colorectal cancer
A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAF V600 wild-type colorectal cancer
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
The relationship between oncogenic KRas and wild-type Ras activity and signaling
[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trial
First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS
Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment
Lobaplatin hyperthermic intraperitoneal chemotherapy plus cytoreduction and rechallenge using cetuximab for wild-type RAS peritoneal metastatic colon cancer: a case report and literature review
Controversies in the treatment of RAS wild-type metastatic colorectal cancer
A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAF V600 wild-type colorectal cancer
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
The relationship between oncogenic KRas and wild-type Ras activity and signaling
[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trial
First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS
Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment
Lobaplatin hyperthermic intraperitoneal chemotherapy plus cytoreduction and rechallenge using cetuximab for wild-type RAS peritoneal metastatic colon cancer: a case report and literature review
Controversies in the treatment of RAS wild-type metastatic colorectal cancer
A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAF V600 wild-type colorectal cancer
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy